EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

Analysis of 2023 World Health Organization cancer Essential Medicines List and concordance with resource-stratified guidelines

Brooke E Wilson iD, Kristin Wright iD, Manju Sengar, Richard Sullivan iD, Sallie-Anne Pearson iD, Michael B Barton iD, Bishal Gyawali iD, Elisabeth De Vries iD, Lorenzo Moja iD, C S Pramesh iD, Christopher M Booth iD

JNCI: Journal of the National Cancer Institute · 01.10.2025 · 117 (10) · 2010-2020

DOI: 10.1093/jnci/djaf100 ↗

Kurz gefasst

Leitlinie in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 23.05.2025. Verfasst von Brooke E Wilson und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Queen's University, Kingston, ON, Canada. Hauptthemen laut MEDLINE: Drugs, Essential, Neoplasms, Practice Guidelines as Topic, Antineoplastic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization, Research Initiation Grant from Queen's University, Research Initiation Grant from Queen’s University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The World Health Organization (WHO) Essential Medicines List (EML) and resource-stratified guidelines both prioritize high-value medicines. We compared the 2023 EML cancer medicines list with global cancer statistics, examined the proportion of EML therapies recommended by resource-stratified guidelines, and identified gaps that merit evaluation by the WHO EML Committee.

Methods

We compared the 2023 EML medicines for adult cancers with cancer incidence and mortality data from GLOBOCAN 2022. We cross-referenced the EML with 2 resource-stratified guidelines (National Comprehensive Cancer Network [NCCN] and National Cancer Grid [NCG] of India) and evaluated preferred treatments in resource-stratified guidelines that were not recommended by the EML.

Results

The 2023 EML included 64 cancer medicines for 219 tumor-specific indications. The greatest number of medicines are listed for leukemia (37/219 [17%]) and lymphoma (33/219 [15%]). Although some common cancers (eg, hepatocellular carcinoma) have no EML-listed medicines because of the low clinical benefit, we identified some cancers (eg, esophageal, gastric) with effective therapies that the EML Committee should evaluate for inclusion. Cancers with no listed medicines make up 34% of cancer deaths globally. Among EML indications with an NCCN resource-stratified guideline, 42% (35/84) and 73% (62/84) were recommended by the NCCN Basic and Core Guidelines, respectively. Among EML indications with an NCG resource-stratified guideline, 163 of 196 (83%) and 175 of 196 (89%) were recommended by the NCG Essential and Optimal guidelines, respectively.

Conclusions

We identified some effective medicines that should be evaluated for inclusion in the WHO EML. Prioritization of cancer medicines was similar between the EML and NCG India but discordant between with NCCN resource-stratified guideline.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drugs, EssentialNeoplasmsPractice Guidelines as TopicAntineoplastic AgentsHumansWorld Health Organization

Substanzen

Drugs, EssentialAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Oncology, Queen's University, Kingston, ON, Canada.
  • Division of Cancer Care and Epidemiology, Queen's Cancer Research Institute, Kingston, ON, Canada.
  • School of Population Health, Faculty of Medicine and Health, UNSW Sydney, Sidney, NSW, Australia.
  • Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, National Cancer Grid, Mumbai, India.
  • Institute of Cancer Policy, King's College London, London, United Kingdom.
  • Department of Oncology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.

ORCID-Profile: Brooke E Wilson, Kristin Wright, Richard Sullivan, Sallie-Anne Pearson, Michael B Barton, Bishal Gyawali, Elisabeth De Vries, Lorenzo Moja, C S Pramesh, Christopher M Booth

Förderung

  • World Health Organization
  • Research Initiation Grant from Queen's University
  • Research Initiation Grant from Queen’s University

Zitieren

APA

Wilson, B. E., Wright, K., Sengar, M., Sullivan, R., Pearson, S. A., Barton, M. B., Gyawali, B., De Vries, E., Moja, L., Pramesh, C. S., & Booth, C. M. (2025). Analysis of 2023 World Health Organization cancer Essential Medicines List and concordance with resource-stratified guidelines. JNCI: Journal of the National Cancer Institute, 117(10), 2010-2020. https://doi.org/10.1093/jnci/djaf100

Vancouver

Wilson BE, Wright K, Sengar M, Sullivan R, Pearson SA, Barton MB, et al. Analysis of 2023 World Health Organization cancer Essential Medicines List and concordance with resource-stratified guidelines. JNCI: Journal of the National Cancer Institute. 2025;117(10):2010-2020. doi:10.1093/jnci/djaf100

BibTeX
@article{Wilson2025,
  author = {Wilson, Brooke E and Wright, Kristin and Sengar, Manju and Sullivan, Richard and Pearson, Sallie-Anne and Barton, Michael B and Gyawali, Bishal and De Vries, Elisabeth and Moja, Lorenzo and Pramesh, C S and Booth, Christopher M},
  title = {Analysis of 2023 World Health Organization cancer Essential Medicines List and concordance with resource-stratified guidelines},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2025},
  volume = {117},
  number = {10},
  pages = {2010--2020},
  doi = {10.1093/jnci/djaf100}
}
Kostenlos starten →